Tofacitinib Combined With Chidamide in R/R ENKTCL

Sponsor
Sichuan University
Study ID
NCT03598959
Phase
PHASE2
Status
Unknown

Conditions

  • Extranodal NK/T-cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
14 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • tofacitinib — DRUG
    orally 10 mg daily
  • chidamide — DRUG
    orally 20 mg twice weekly

Study Details

This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.

Key Dates

Start date
Jan 1, 2019
Status verified
Jul 2018
Primary completion
Dec 31, 2019
Completion
Dec 31, 2021

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Treated with tofacitinib and chidamide for 4 cycles.

Primary Outcome Measure

2-year progression free survival [ Time Frame: 2 years after recruitment ]

Central Contacts